[1] Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. DOI:
10.1200/JCO.21.00662[2] Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models ofEGFRExon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DOI:
10.1158/2159-8290.CD-20-0116